Yeung MW, Tuite A, Nam A, Ximenes R, Arthurs E, Awan A, Khaliq S, Loukov D, Carrico J, Hicks K. Cost-effectiveness analyses for SHINGRIX (RZV) in 18+ IC populations in Canada. Presented at National Advisory Committee on Immunization Herpes Zoster Working Group; November 1, 2021. Virtual.